Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.55M | -640.80K | -1.61M | -1.72M | -1.68M |
| Total Depreciation and Amortization | 12.60K | 12.60K | 12.60K | 12.60K | 26.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 10.20K |
| Total Other Non-Cash Items | 165.00K | 250.40K | 213.90K | 161.70K | 671.50K |
| Change in Net Operating Assets | 556.40K | 192.10K | -171.80K | -109.10K | -176.60K |
| Cash from Operations | -819.80K | -185.70K | -1.55M | -1.66M | -1.14M |
| Capital Expenditure | -- | -- | -- | -- | -94.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 1.60M | 1.20M | 2.37M |
| Cash from Investing | 0.00 | 0.00 | 1.60M | 1.20M | 2.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.60M | 317.00K | 44.50K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.60M | 317.00K | 44.50K | -- | -- |
| Foreign Exchange rate Adjustments | 400.00 | -100.00 | 200.00 | 200.00 | 900.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 782.70K | 131.20K | 92.80K | -456.10K | 1.13M |